The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called RO4929097 at different dose levels, when added to the standard treatment for newly diagnosed glioma in patients who will be having surgery. This standard treatment consists of radiotherapy combined with temozolomide, a drug used to treat gliomas. Radiotherapy and temozolomide are the current standard treatment for these brain cancers.